Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Eli Lilly and Company
NCT06043817 · Non-Small Cell Lung Cancer, NSCLC, and more
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT05671510 · Non Small Cell Lung Cancer
NCT06257264 · Breast Cancer, Small Cell Lung Cancer, and more
NCT07144280 · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, and more
Highlands Oncology Group
Fayetteville, Arkansas
Rocky Mountain Cancer Center
Denver, Colorado
H Lee Moffitt Cancer Center
Tampa, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions